Proteins and pathways in atrial fibrillation and atrial cardiomyopathy underlying cryptogenic stroke

Elena Palà a,1, Jorge Pagola b,1, Jesus Juega b,1, Jaume Francisco-Pascual c,d,1, Anna Penalba a,1, Maite Rodriguez b,1, Mercedes De Lera Alfonso a,1, Juan F. Arenillas a,1, Juan Antonio Cabezas f,1, Francisco Moniche f,1, Reyes de Torres g,1, Soledad Perez-Sanchez g,1, Teresa González-Alujas d,h,1, Carlos A. Molina b,1, Alejandro Bustamante a,1, Joan Montaner a,1,6

ABSTRACT

Background: Atrial fibrillation (AF) is one of the most prevalent causes of cryptogenic stroke. Also, apart from AF itself, structural and remodelling changes in the atria might be an underlying cause of cryptogenic stroke. We aimed to discover circulating proteins and reveal pathways altered in AF and atrial cardiomyopathy, measured by left atrial volume index (LAVI) and peak atrial longitudinal strain (PALS), in patients with cryptogenic stroke.

Methods: An aptamer array (including 1310 proteins) was measured in the blood of 20 cryptogenic stroke patients monitored during 28 days with a Holter device as a case-control study of the Crypto-AF cohort. Protein levels were compared between patients with (n = 10) and without AF (n = 10) after stroke, and the best candidates were tested in 111 patients from the same cohort (44 patients with AF and 67 without AF). In addition, in the first 20 patients, proteins were explored according to PALS and LAVI values.

Results: Forty-six proteins were differentially expressed in AF cases. Of those, four proteins were tested in a larger sample size. Only DPP7, presenting lower levels in AF patients, was further validated. Fifty-seven proteins correlated with LAVI, and 270 correlated with PALS. NT-proBNP was common in all the discovery analyses performed. Interestingly, many proteins and pathways were altered in patients with low PALS.

Conclusions: Multiple proteins and pathways related to AF and atrial cardiomyopathy have been revealed. The role of DPP7 as a biomarker for stroke aetiology should be further explored. Moreover, the present study may be considered hypothesis-generating.

ARTICLE INFO

Keywords:
Atrial fibrillation
Atrial cardiomyopathy
Cryptogenic stroke
Atrial function

1. Introduction

Atrial fibrillation (AF) is a prevalent cardiac rhythm disorder underlying up to one-third of all ischemic strokes [1]. Paroxysmal AF remains undetected in a high proportion of patients after stroke and is one of the most prevalent causes of cryptogenic stroke [2].

Also, there is increasing recognition that atrial dysfunction itself is associated with an increased risk of thromboembolism, even in patients...
without AF [3]. Therefore, atrial substrate or atrial cardiomyopathy has been proposed as an important cause of cryptogenic strokes [4,5].

Left atria (LA) enlargement and atrial fibrosis are two structural hallmarks of the atrial substrate [3]. LA size has been associated with cardiogenic stroke and AF detection in patients with embolic stroke of undetermined source (ESUS) [6]. Similarly, peak atrial longitudinal strain (PALS), which measures the LA wall deformability and is a surrogate of LA fibrosis, has been associated with AF in cryptogenic stroke patients [7].

Some blood biomarkers (e.g., natriuretic peptides) have been proposed as useful tools to detect paroxysmal AF [8]. In addition, circulating markers might allow noninvasive assessment of atrial cardiomyopathy before AF appears and might guide the selection of patients for more intensive post-stroke monitoring to personalize the secondary prevention treatments [2,5].

The present study aims to discover circulating proteins and reveal pathways altered in AF and atrial cardiomyopathy, measured by left atrial volume index (LAVI) and PALS, in patients with cryptogenic stroke.

2. Methods

2.1. Study population

The study population represented a subpopulation of the Crypto-AF study [9,10]. Non-lacunar acute ischemic stroke patients over 55 years of age with cryptogenic stroke after standard evaluation were included in the study by four Spanish public Stroke Centers from January 2015 to July 2017. All patients included had no prior history of AF. Patients were monitored for 28 days with a wearable Holter device (Nuubo® in the study by four Spanish public Stroke Centers from January 2015 to 2016). Combined Coefficient (Combined Coefficient) was determined by a commercial control (Human Serum, male AB, USA origin from clotted, SIGMA, ref number H16914; Human plasma K2 EDTA, Innovative Research, ref number IPLA-N) tested in duplicate in each plate. When inter-assay variation was > 20%, biomarker levels were standardized by the common control sample. Samples with a CV (coefficient of variation) > 20% between duplicates were eliminated from the analysis.

2.2. Aptamer array

Protein levels in plasma were assessed using the SOMAser"® platform (SomaLogic Inc., Boulder, CO, USA), which is an aptamer-based proteomic assay that allowed the simultaneous measurement and quantification of 1310 proteins [13]. This approach uses SOMAser® reagents, which are short single-stranded DNA sequences with protein affinity. The platform transforms the proteins present in the biological sample into a corresponding SOMAser signal, which then is quantified using the microarrays technology. Three different dilutions (depending on each protein abundance) were used. Normalization and calibration procedures were performed by SomaLogic according to their protocol [14]. All samples passed SomaLogic quality controls. A set of control calibrator samples were used to detect and remove systematic variability between independent assay runs. Seventy-nine proteins were marked as “flags” due to high inter-plate variability and eliminated from the analysis. Data were reported in relative fluorescent units (RFU) after normalization and calibration.

2.3. Elisa

Serum coiled-coil domain-containing protein 80 (CCDC80)(Bos-terBio), and plasma dipeptidyl peptide 7 (DPP7)(R&D Systems), bone morphogenetic protein 1 (BMP-1)(Elabscience), and cystatin-D (Bos-terBio) were determined by ELISA. All assays were performed blinded to clinical information and according to the manufacturer’s instructions. All samples were tested in duplicate, and inter-assay variation was determined by a commercial control (Human Serum, male AB, USA origin from clotted, SIGMA, ref number H16914; Human plasma K2 EDTA, Innovative Research, ref number IPLA-N) tested in duplicate in each plate. When inter-assay variation was > 20%, biomarker levels were standardized by the common control sample. Samples with a CV (coefficient of variation) > 20% between duplicates were eliminated from the analysis.

2.4. Statistics

R software version 3.6.1 and SPSS version 20 were used to conduct statistical analysis. Categorical variables were expressed as numbers and percentages and continuous variables as mean ± SD, or median (interquartile range) for continuous variables, depending on their distribution. Student’s t-test, Mann–Whitney or x² were used to compare variables between AF cases and controls depending on the type and distribution of each variable.

SOMAser data were log-transformed as presented a skewed distribution. Differential expression analyses were performed using the “limma” package (Bioconductor) version 3.42.2, optimized for omics studies with large amounts of data and few samples [15]. Spearman correlations were calculated between LAVI or PALS and all the analyzed proteins. The R package “Venndiagram” version 1.6.20 was used to visualize the common proteins between the different analyses. All p-values were adjusted using Benjamini and Hochberg (BH) false discovery rate (FDR). Group matching by sex and age was used to select control samples in the discovery experiment. The validation sample size was estimated based on Somascan results (power of 80%, α = 0.05) (Ene 3.0, GlaxoSmithKline, UK).

The addition of DPP7 to a logistic regression model fitted by age, sex, echocardiographic markers (LAVI and PALS), and NT-proBNP was tested using the Likelihood Ratio Test. Odds ratios (OR) for an increment of one unit of concentration were shown. The classification performance of the models was compared using Receiver Operating Curves. The R package “ggeffects” version 1.1.1 was used to plot the average predicted probability of the model when varying the variable of interest.

2.5. Pathway analysis

Pathway enrichment analysis was conducted following a published protocol [16]. Gene Set Enrichment Analysis (GSEA) software was applied to all the SOMAser proteins ordered by T-statistic or correlation coefficient against Reactome Pathways and Gene Ontology (biological processes) databases. Gene sets with < 15 genes or ≥ 200 genes were excluded. GSEA calculates a normalized enrichment score (NES) for each gene set. Positive and negative NES values represent enrichment of the corresponding gene set at the top (i.e., upregulated) or bottom (i.e., downregulated) of the ranked list. P-values were computed by gene set permutation for 1000. Then, multiple testing using a false-discovery rate (FDR) was applied to obtain the Q-values. Results were visualized via Cytoscape Enrichment Map with a Jaccard Overlap Combined Coefficient > 0.375. Significant pathways were considered at Q-value < 0.25.
3. Results

The descriptive characteristics of the 20 patients included in the discovery study are provided in Table 1. The median age was 71.5, and 55% were women. Clinical variables were similar between the two groups.

3.1. Differential protein expression and altered pathways in AF

Among the tested proteins, 46 were differentially expressed in AF cases at a nominal p-value of 0.05 (22 down-regulated and 24 up-regulated). Although no protein remained significant after multiple comparison correction, NT-proBNP showed the strongest association (p-value = 0.0013), DPP7 (p-value = 0.0039), BMP-1 (p-value = 0.0051), and Cystatin-D (p-value = 0.0080) (Fig. 1 and Supplemental Table 1).

GSEA analysis revealed five gene sets upregulated in patients with AF (Regulation of cellular response to growth factor stimulus, Lymphocyte chemotaxis, Calcium ion transmembrane transport, Lymphocyte migration, Chemokine receptors bind chemokines), and five gene sets downregulated (Binding and Uptake of Ligands by Scavenger Receptors, Interleukin-12 family signalling, Vesicle-mediated transport, Transport of small molecules and Interleukin-12 signalling). Most altered pathways were related to immune response and intracellular transport (Supplemental Fig. 1).

Table 1

|                          | All (n = 20) | AF (n = 10) | No AF (n = 10) | p-value |
|--------------------------|-------------|------------|---------------|---------|
| Sex (%female)            | 11 (55%)    | 6 (60%)    | 5 (50%)       | 0.65*   |
| Age (years)              | 71.5        | 73.5 (69.75–80) | 67.5       | 0.249†  |
| Hypertension             | 14 (70%)    | 7 (70%)    | 7 (70%)       | 1.00*   |
| Diabetes                 | 5 (25%)     | 3 (30%)    | 2 (20%)       | 1.00*   |
| Vasculopathy             | 1 (5%)      | 0 (0%)     | 1 (10%)       | 1.00*   |
| Renal failure            | 1 (5.3%)    | 1 (11.1%)  | 0 (0%)        | 0.47‡   |
| COPD                     | 1 (5.3%)    | 1 (11.1%)  | 0 (0%)        | 0.47‡   |
| Obesity                  | 8 (40%)     | 5 (50%)    | 3 (30%)       | 0.65‡   |
| Heart disease            | 2 (10%)     | 2 (20%)    | 0 (0%)        | 0.47‡   |
| Basal NIHSS              | 4 (2–7)     | 3 (1–7)    | 5 (3–7)       | 0.29*   |
| LVEF (%)                 | 64.74 ± 34.19 | 63 ± 7.84  | 66.30 ± 7.51  | 0.362†  |
| PALS (%)                 | 25.76 ± 12.98 | 29.89 ± 14.06 | 20.59 ± 10.00 | 0.134*  |
| LAVI (mL/m²)             | 31 (27–34)  | 30 (27–34) | 34 (22.5–37.75)| 0.815*   |
| Number of AF episodes    | 28 (7–42.5) |           |               |         |
| Longest AF episode (min) | 780.48 (121.25–150.71)| |               |         |

COPD, chronic obstructive pulmonary disease; NIHSS, National Institutes of Health Stroke Scale; LVEF, left ventricular ejection fraction; PALS, peak atrial longitudinal strain; LAVI, left atrial volume index.

The “heart disease” terminology included any cardiopathy that the investigator considered of interest, including into this category ischemic cardiopathy, and hypertensive cardiopathy, between others. The two patients with heart disease in this cohort had a mild mitral and aortic valvulopathy, and a hypertensive cardiomyopathy respectively.

* Student’s t-test.
† Mann-Whitney test.
‡ x² test.

3.1.1. Biomarker validation

The clinical characteristics of the 111 patients included in the validation study were provided in Supplemental Table 2. This subgroup was older (p = 0.021) and had a lower percentage of obesity (p = 0.041) in comparison to the discovery cohort. Several samples had a CV > 20% between duplicates and were eliminated from the analysis accordingly. Therefore, we had a final sample size of 107 patients for CCDC80, 86 for DPP7, 95 for BMP1, and 97 for Cystatin-D. Levels from the four biomarkers were available from 74 patients. Analysis was performed with the patients available for each biomarker. DPP7 was significantly lower in individuals with AF compared with no AF [5.13 ng/ml (IQR 3.42–7.10) vs 6.16 ng/ml (5.04–8.39), p = 0.013], while the remaining biomarkers were not different between the two groups (Fig. 2 and Supplemental Table 3). Sensitivity analyses were performed only, including the patients with values from all the biomarkers, obtaining similar results.

DPP7 alone was a predictor of AF (OR = 0.828 per ng/ml [0.695–0.986], p = 0.034). Then, when adding DPP7 to a logistic regression model fitted with age, sex, PALS, LAVI, and NT-proBNP, it remained an independent predictor (OR = 0.729 per ng/ml [0.539–0.988], p = 0.041). This model, including DPP7, showed better fit according to the likelihood ratio test (χ² = 6.001, p = 0.041), and the AUC increased, although the DeLong test was not significant (0.657 [0.484–0.831] vs 0.756 [0.608–0.904], p = 0.155). The models were built with 51 complete cases with all the variables available (17 AF and 34 no AF) (Supplemental Fig. 2).

3.2. Differential protein expression and altered pathways in atrial myopathy

3.2.1. LAVI

Fifty-seven proteins correlated significantly with LAVI (40 negative correlations and 17 positive correlations). From these, only 17 had a correlation coefficient r > 0.6. No proteins remained significant after multiple corrections in any of the analyses (Supplemental Table 4 and Supplemental Fig. 3).

The pathway analysis, considering the protein list ordered by the correlation coefficient between protein levels and LAVI, revealed only
one gene set upregulated with LAVI with a Q-value < 0.25: Netrin-1 signalling (R-HSA-373752).

3.2.2. PALS

Two-hundred-seventy proteins correlated significantly with PALS (117 negative correlations and 153 positive correlations). From these, only 64 had a correlation coefficient $r > |0.6|$, and six remained significant after multiple comparison corrections (Supplemental Table 5 and Supplemental Figure 4).

When proteins were ordered by the correlation coefficient between
protein levels and PALs, 264 gene sets were enriched in patients with high PALs, and two were enriched in patients with low PALs (R-HSA-1630316, Glycosaminoglycan metabolism, and R-HSA-3781865, Diseases of Glycosylation). Dysregulated pathways were mostly involved in signal transduction, metabolism, immune response, and hemostasis. (Supplemental Table 6 and Supplemental Figure 5).

3.3. Common protein expression in AF and atrial myopathy

NT-proBNP was the only protein common in all the analyses performed. Five proteins were related to LAVI and PALs (Leukotriene A-4 hydrolase, Alpha-2-macroglobulin, Histone H2A type 3, Secretin, and Fibroblast growth factor 12). One protein was associated with AF and LAVI (Cell adhesion molecule 3). Fourteen proteins were associated with AF and PALs (Urokinase plasminogen activator surface receptor, Lumican, Dermatopontin, Follicatin-related protein 3, C-C motif chemokine 25, Plasminogen, Coagulation factor VII, Natural killer cell receptor 2B4, Angiopoietin-2, Interleukin-23 receptor, Brain natriuretic peptide 32, Erythropoietin, Advanced glycosylation end product-specific receptor, and Macrophage mannose receptor 1) (Fig. 3).

4. Discussion

In the present study, a wide variety of proteins have been explored in a cohort of cryptogenic stroke patients monitored for 1 month to detect AF. Although several studies had previously explored individual biomarkers of cardioembolic stroke and/or AF in stroke patients [17], few studies had used a discovery approach to identify new candidates related to occult AF. In fact, the majority of AF “discovery” studies enrolled asymptomatic patients [18–20] and, to our knowledge, only the study of Lambert et al. included stroke patients [21]. This study explored 184 proteins in patients with previously known causes of stroke. In contrast, we evaluated a wider range of proteins in patients with ESUS to ascertain new predictors of AF. Although all the patients included in our study had no prior story of AF, we cannot differentiate between new-onset AF or first-diagnosed AF. However, we aimed to identify AF cases in cryptogenic stroke patients independently of the onset of this AF because, from a clinical perspective, the treatment of the arrhythmia is the same.

Regarding the proteins differentially expressed in our analysis when comparing patients with and without AF, we should highlight that natriuretic peptides, NT-proBNP and BNP, were in the top-ranked positions. Both are well-known surrogates of AF and have already been validated in the present cohort of cryptogenic patients [8]. Therefore, we decided to test other proteins with similar nominal p-values in the comparison. Only DPP7 showed significant differences in the validation from the four proteins selected, with higher levels in the patients without AF. DPP7 (also called DPP2) is a member of the dipetidyl peptidase family, which has been implicated in many immunologic processes. Although limited data about DPP7 is available compared to conventional immunoassays as previous studies presented weak correlations (r < 0.3) in some proteins between SOMAscan platform and conventional immunoassays [24]. The low reproducibility between techniques may be explained as binding reagents interacting with different epitopes of a specific analyte. That is why discovery studies aiming to find biomarker candidates should include validations with different techniques. More importantly, the difficulty to find new AF biomarkers with “discovery” strategies may be due to the complexity of AF, which makes it challenging to classify the patients in a binary variable. First, we cannot discard there were false-negative cases in the no AF group as cardiac monitoring might not have been prolonged enough to detect some AF cases [25]. Also, AF could be just a bystander, and atrial dysfunction is the real underlying disease that causes stroke susceptibility [26]. Consequently, there is a need to search for biomarkers that identify not only AF but also the underlying atrial substrate. Therefore, and taking advantage of the availability of well-phenotyped patients by echocardiography, we have explored circulating proteins and functional pathways that might be associated with atrial cardiomyopathy. Two echocardiographic variables have been considered to perform this analysis: LAVI and PALs. Although evaluating different characteristics of the left atria, both variables are used to identify atrial myopathy and have been shown useful to predict AF [3]. LAVI measures the enlargement of the atria while PALS provides information on its deformability, but both variables are highly related. Interestingly, in our analysis, while many proteins and pathways were altered in patients with lower PALs, few were affected in patients with high LAVI. This may reflect that more pathophysiological changes are behind the remodelling that results in atrial distensibility impairment compared to atrial enlargement. Previous studies stated that PALs measurements were more sensitive than volumetric measurements to predict AF and that LA dysfunction may precede and/or be independent of anatomical changes like LA enlargement [27]. This may also explain why few protein candidates are associated with both variables in our analysis.

The bioinformatics analysis revealed some interesting pathways playing a role in AF and atrial cardiomyopathy. The study highlighted the importance of the inflammatory response in AF, especially the role of lymphocytes and chemokine signalling. This confirms the role of inflammation in the initiation and maintenance of AF, which has extensively been described [28]. Also, we found an enrichment of growth factors signalling, which can also be linked to the inflammatory response or the fibrosis occurring in the heart [29]. Finally, calcium handling is essential for the correct electrical functioning of the heart, and similarly of what we found, abnormal calcium handling can lead to cardiac arrhythmias like AF [30].

On the other hand, several pathways were downregulated in the AF group compared to the no AF group, which could be related to other stroke etiologies in the second group. This is the case of interleukin-12 (IL-12) signalling. Interleukin-12 family members have been related to various cardiovascular diseases, including atherosclerosis, hypertension, aortic dissection, and several cardiac pathologies [31]. Also, in patients without AF, we found an upregulation of vesicle-mediated intracellular transport and activity of scavenger receptors, which are membrane-bound receptors that bind a variety of ligands, including low-density-lipoproteins (LDL). These, together with the transport of small molecules, are pathways that might describe increased levels of LDL, involved in atherosclerosis, in patients without AF.

4.1. Study limitations

The present study has several limitations. The main limitation is the...
small size sample, limiting our statistical power to correct multiple comparisons. Second, the selection of patients was performed according to AF diagnosis, and then a posterior exploratory analysis according to echocardiographic variables was performed. As continuous variables, correlations between the echocardiographic variables and protein levels were assessed, but we should consider the difficulties of obtaining significant correlations with a reduced sample size. The same reason precluded sex- and age-based analysis. Therefore, we cannot eliminate the effect of age on the proteins/pathways revealed, especially in the case of left atrial strain that correlates with age. Nevertheless, we may not be interested in eliminating this effect as fibrosis of the atrium is a cumulative process that may result from pathways altered with age.

Similarly, LAVI is larger in women than in men in our cohort, and the association of some proteins’ abundance with LAVI may reflect sex differences in our population. Therefore, these results need to be interpreted as hypotheses-generating. Selection of patients according to extreme PALS and LAVI matched by sex and age and validation of altered markers in a cohort with a longer follow-up would provide further insights. Moreover, we should state that LAVI and PALS might not be specific markers of atrial cardiomyopathy. Other parameters and techniques can be used to characterize the disease in other studies (e.g., left atrial voltage mapping, late gadolinium-enhanced magnetic resonance imaging, and histological analysis).

Also, the lack of a matched set of similar aged non-stroke patients limits insight into biomarkers specifically associated with stroke. Finally, we only analyzed a small portion of the full proteome, which may have conditioned our findings.

5. Conclusions

The present study revealed multiple proteins and pathways that may have a role in the development of atrial fibrillation. In particular, the role of DPP7 as a biomarker for stroke aetiology should be further explored. Also, we have proposed a strategy considering echocardiographic parameters to discover new biomarkers and pathways that may have a role in atrial fibrillation and atrial myopathy. In this regard, the present study can be interpreted as hypotheses-generating. Selection of patients according to sex- and age-based analysis. Therefore, we cannot eliminate the significant correlations with a reduced sample size. The same reason prevents specific markers of atrial cardiomyopathy. Other parameters and techniques can be used to characterize the disease in other studies (e.g., left atrial voltage mapping, late gadolinium-enhanced magnetic resonance imaging, and histological analysis).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This work was supported by the Instituto de Salud Carlos III, Spain [grant number PI15/02265 and PI18/00804]. The Spanish stroke research network INVICTUS+ (RD16/0019/00021) of the Instituto de Salud Carlos III (co-financed by the European Regional Development Fund, FEDER) is also acknowledged. EP has received a predoctoral grant from Vall D’Hebron Institute of Research. This project is supported by AFFECT-EU, receiving funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 847770. Sponsors did not have any role in the study design, analysis, interpretation of data, writing, or the decision to submit the article for publication.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijcha.2022.1009977.

References

[1] B. Freedman, T.S. Potpara, G.Y.H. Lip, Stroke prevention in atrial fibrillation, Lancet 388 (10046) (2016) 806–817, https://doi.org/10.1016/S0140-6736(16)31257-6.
[2] R.B. Schnabel, K.G. Haeteler, J.S. Healey, et al., Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN International Collaboration, Circulation 140 (2019) 1834–50, https://doi.org/10.1161/CIRUHJ.119.014026.
[3] J.J. Goldberg, R. Arora, D. Green, P. Greenland, D.C. Lee, D.M. Lloyd-Jones, M. Markl, J. Ng, S.J. Shah, Evaluating the atrial myopathy underlying atrial fibrillation: Identifying the arrhythmogenic and thrombogenic substrate, Circulation 134 (2) (2015) 278–281.
[4] M.S.V. Elkind, Atrial cardiopathy and stroke prevention, Curr. Cardiol. Rep. 20 (11) (2018), https://doi.org/10.1007/s11886-018-1053-0.
[5] K. Jordan, S. Yaghi, A. Pappas, A.D. Chang, B. Mac Groey, S. Cutting, T. Burton, M. Jayaraman, G. Tsvigoulis, M.K. Sabe, A.E. Merkler, H. Kamel, M.S.V. Elkind, K. Furie, C. Song, Left atrial volume index is associated with cardioembolic stroke and atrial fibrillation detection after embolic stroke of undetermined source, Stroke 50 (8) (2019) 1997–2001, https://doi.org/10.1161/STROKEAHA.119.025384.
[6] J. Pagola, T. Gonzalez-Alujas, A. Flores, M. Muchada, D. Rodriguez-Luna, L. Sero, M. Rubiera, S. Boned, M. Ribe, J. Alvarez-Sabin, A. Evangelista, C.A. Molina, Left Atria Strain Is a Surrogate Marker for Detection of Atrial Fibrillation in Cryptogenic Strokes, Stroke 45 (8) (2014), https://doi.org/10.1161/STROKEAHA.114.005540.
[7] E. Palà, J. Pagola, J. Juega, et al., BNP over NT-proBNP to predict incident atrial fibrillation after cryptogenic stroke, Eur. J. Neurol. 2020;ene.14579. doi:10.1111/ene.14579.
[8] J. Pagola, J. Juega, J. Francisco-Pascual, et al., Yield of atrial fibrillation detection with Textile Wearable Holter from the acute phase of stroke: Pilot study of CryptoAF registry, Int. J. Cardiol. 251 (2018) 45–50. doi:10.1016/j.ijcard.2017.10.063.
[9] J. Pagola, J. Juega, J. Francisco-Pascual, A. Bustamante, A. Penalba, E. Palà, M. Rodríguez, M. De Lera Alfonso, J.F. Arenillas, J.A. Cabezas, F. Moniche, R. Torres, J. Montaner, T. Gonzalez-Alujas, J. Alvarez-Sabin, C.A. Molina, Large vessel occlusion is independently associated with atrial fibrillation detection, Eur. J. Neurol. 27 (8) (2020) 1618–1624, https://doi.org/10.1111/ene.14281.
[10] E. Donal, G.Y.H. Lip, M. Galdersi, A. Goette, D. Shah, M. Marwan, M. Lederlin, S. Mondillo, T. Edvardsen, M. Stiges, J. Grapua, M. Garbi, R. Sinner, A. Gimelli, T. S. Fogtara, I.C. Van Gelder, B. Gorenek, P. Mabo, P. Lanczlooti, K.-H. Kuck, B. A. Popescu, G. Hindricks, G. Habib, B. Cosyns, V. Delgado, K.H. Haugaa, D. Muraru, K. Nierman, A. Cohen, EAVCI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation, Eur. Heart J. Cardiovasc. Imaging 17 (4) (2016) 355–383, https://doi.org/10.1093/ehjci/jev354.
[11] F. Pathan, N. D’Elia, M.T. Nolan, T.H. Marwick, K. Ngishi, Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis, J. Am. Soc. Echocardiogr. 30 (1) (2017) 59–70.8. https://doi.org/10.1016/j.echo.2016.09.007.
[12] L. Gold, D. Ayers, J. Bertino, et al., Aptamer-based multiplexed proteomic technology for biomarker discovery, PLoS One 5 (2010). doi:10.1371/journal.pone.0001504.
[13] J. Candra, F. Cheung, Y. Kotiani, G. Fontoni, B. Sellers, T. Griesman, J. Huang, S. Stuccio, A. Zingone, B.M. Ryan, J.S. Tsang, A. Biancotto, Assessment of variability in the SOMAscan assay, Sci. Rep. 7 (1) (2017), https://doi.org/10.1038/s41598-017-14755-5.
[14] G.K. Smyth, Linear models and empirical bayes methods for assessing differential expression in microarray experiments, Stat. Appl. Genet. Mol. Biol. 3 (2004) doi:10.2202/1544-6115.1027.
[15] J. Reimand, R. Iserlin, V. Voisins, M. Kucera, V. Bjerkeli, K. Skagen, M. Coq, E. Schordan, H. Firat, B. Halvorsen, A. Aamodt, Lebensalter, W. Barbara, N. Sednaoui, J. Juega, et al., BNP over NT-proBNP to predict incident atrial fibrillation after cryptogenic stroke, Eur. J. Neurol. 2020;ene.14579. doi:10.1111/ene.14579.
[16] E. Palà, A. Tancin Lambert, X. Kong, B. Ratajczak-Tretel, D. Atar, D. Russell, M. Skjelland, V. Bjerkeli, K. Skagen, M. Coq, E. Schordan, H. Firat, B. Halvorsen, A. Aamodt, Biomarkers associated with atrial fibrillation in patients with ischemic stroke: a pilot study from the NOR-FIB Study, Cerebrovasc Dis Extra 10 (1) (2020) 11–20, https://doi.org/10.1159/000450529.
Y. Waumann, L. Baerts, K. Kehoe, A.-M. Lambeir, I. De Meester, The dipeptidyl peptidase family, prolyl oligopeptidase and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis, Front. Immunol. 6 (2015), https://doi.org/10.3389/fimmu.2015.00387.

M.-B. Maes, S. Scharpé, I. De Meester, Dipeptidyl peptidase II (DPPII), a review, Clin. Chim. Acta 380 (1-2) (2007) 31–49, https://doi.org/10.1016/j.cca.2007.01.024.

L.M. Raffield, H. Dang, K.A. Pratte, et al., Comparison of proteomic assessment methods in multiple cohort studies, Proteomics 20 (2020) 1–34. doi:10.1002/pmic.201900278.

E. Pal et al.